1
|
Usart M, Stetka J, Luque Paz D, Hansen N, Kimmerlin Q, Almeida Fonseca T, Lock M, Kubovcakova L, Karjalainen R, Hao-Shen H, Börsch A, El Taher A, Schulz J, Leroux JC, Dirnhofer S, Skoda RC. Loss of Dnmt3a increased self-renewal and resistance to pegIFNα in JAK2-V617F-positive myeloproliferative neoplasms. Blood 2024:blood.2023020270. [PMID: 38493481 DOI: 10.1182/blood.2023020270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 02/23/2024] [Accepted: 02/26/2024] [Indexed: 03/19/2024] Open
Abstract
Pegylated interferon alpha (pegIFNα) can induce molecular remissions in JAK2-V617F-positive myeloproliferative neoplasms (MPN) patients by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A, have been reported to have poorer responses to pegIFNα. We investigated if DNMT3A loss leads to alterations in JAK2-V617F LT-HSCs functions conferring resistance to pegIFNα treatment in a mouse model of MPN and in hematopoietic progenitors from MPN patients. Long-term treatment with pegIFNα normalized blood parameters, reduced splenomegaly and JAK2-V617F-chimerism in single-mutant JAK2-V617F (VF) mice. However, pegIFNα in VF;Dnmt3aΔ/Δ (VF;DmΔ/Δ) mice worsened splenomegaly and failed to reduce JAK2-V617F-chimerism. Furthermore, LT-HSCs from VF;DmΔ/Δ mice compared to VF were less prone to accumulate DNA damage and exit dormancy upon pegIFNα treatment. RNA-sequencing showed that IFNα induced stronger upregulation of inflammatory pathways in LT-HSCs from VF;DmΔ/Δ compared to VF mice, indicating that the resistance of VF;DmΔ/Δ LT-HSC was not due to failure in IFNα signaling. Transplantations of bone marrow from pegIFNα treated VF;DmΔ/Δ mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from MPN patients with JAK2-V617F and DNMT3A mutation showed increased percentages of JAK2-V617F-positive colonies upon IFNα exposure, whereas in patients with JAK2-V617F alone the percentages of JAK2-V617F-positive colonies decreased or remained unchanged. PegIFNα combined with 5-azacytidine only partially overcame resistance in VF;DmΔ/Δ mice. However, this combination strongly decreased the JAK2-mutant allele burden in mice carrying VF mutation only, showing potential to inflict substantial damage preferentially to the JAK2-mutant clone.
Collapse
Affiliation(s)
- Marc Usart
- University Hospital Basel and University of Basel, Basel, Switzerland
| | - Jan Stetka
- University Hospital Basel and University of Basel, Switzerland, Basel, Switzerland
| | - Damien Luque Paz
- Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, France, ANGERS, France
| | - Nils Hansen
- University Hospital of Basel, Basel, Switzerland
| | - Quentin Kimmerlin
- University Hospital Basel and University of Basel, Basel, Switzerland
| | | | - Melissa Lock
- University Hospital Basel and University of Basel, Switzerland, Basel, Switzerland
| | - Lucia Kubovcakova
- University Hospital Basel and University of Basel, Basel, Switzerland
| | - Riikka Karjalainen
- University Hospital Basel and University of Basel, Switzerland, Basel, Switzerland
| | - Hui Hao-Shen
- Swiss Institute of Bioinformatics, Basel, Switzerland, Switzerland
| | | | - Athimed El Taher
- University Hospital Basel and University of Basel, Basel, Switzerland
| | | | | | | | - Radek C Skoda
- University Hospital Basel and University of Basel, Basel, Switzerland
| |
Collapse
|
2
|
Malani D, Kumar A, Yadav B, Kontro M, Potdar S, Bruck O, Kytölä S, Saarela J, Eldfors S, Karjalainen R, Majumder MM, Västrik I, Ellonen P, Kankainen M, Suvela M, Knappila S, Parson A, Palva A, Mattila P, Kulesskiy E, Turunen L, Laamanen K, Lehtinen E, Nurmi M, Suomi K, Muruimägi A, Gjertsen BT, Mustjoki S, Anders S, Wolf M, Aittokallio T, Wennerberg K, Heckman C, Porkka K, Kallioniemi O. Abstract 458: Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex-vivo drug sensitivity testing and molecular profiling. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Acute myeloid leukemia (AML) is an aggressive disease of clonal hematopoietic progenitor cells. Here, we applied ex-vivo drug sensitivity and resistance testing on AML patient cells with 362 emerging and 153 approved cancer drugs together with genomic and transcriptomic profiling to identify and tailor therapies for patients with advanced disease. Ex-vivo testing with freshly isolated patient cells revealed cancer-specific efficacies of approved drugs in 97% of the 164 patient cases, including 47% of the cases with no actionable driver mutations. We identified 142 statistically significant associations between drug responses and somatic mutations, including increased sensitivity to JAK inhibitors in patients with NPM1 mutations. Transcriptomic profiles predicted drug responses better than genomics and helped to identify additional response markers, especially beyond mutations. For example, overexpression of HOX family genes was associated with sensitivity to JAK inhibitors in patients with NPM1 mutation. In a prospective study, we translated the functional drug response and molecular profile data to the clinic and suggested tailored therapy with targeted drugs for 26 relapsed or refractory AML patients. In an observational intervention study, acting on these recommendations resulted in a temporary complete clinical remission or leukemia-free state in 39% of the cases. In summary, we conclude that ex-vivo testing of drugs on patient AML cells i) revealed clinically actionable drug efficacies in almost all AML patients, including patients with no actionable mutations, ii) predicted cases with actionable driver mutations with no pharmacological dependency on the target, and iii) enabled real-time tailoring of therapy with 39% clinical response rate in chemorefractory advanced AML. Taken together, we believe this real-time systems medicine approach could become a powerful strategy for tailoring therapies for individual patients in the future.
Citation Format: Disha Malani, Ashwni Kumar, Bhagwan Yadav, Mika Kontro, Swapnil Potdar, Oscar Bruck, Säri Kytölä, Jani Saarela, Samuli Eldfors, Riikka Karjalainen, Muntasir M. Majumder, Imre Västrik, Pekka Ellonen, Matti Kankainen, Minna Suvela, Siv Knappila, Alun Parson, Aino Palva, Pirkko Mattila, Evgeny Kulesskiy, Laura Turunen, Karoliina Laamanen, Elina Lehtinen, Maria Nurmi, Katja Suomi, Astrid Muruimägi, Bjorn T. Gjertsen, Satu Mustjoki, Simon Anders, Maija Wolf, Tero Aittokallio, Krister Wennerberg, Caroline Heckman, Kimmo Porkka, Olli Kallioniemi. Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex-vivo drug sensitivity testing and molecular profiling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 458.
Collapse
Affiliation(s)
- Disha Malani
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Ashwni Kumar
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Bhagwan Yadav
- 2Hematology Research Unit Helsinki, Helsinki, Finland
| | - Mika Kontro
- 2Hematology Research Unit Helsinki, Helsinki, Finland
| | - Swapnil Potdar
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Oscar Bruck
- 2Hematology Research Unit Helsinki, Helsinki, Finland
| | - Säri Kytölä
- 2Hematology Research Unit Helsinki, Helsinki, Finland
| | - Jani Saarela
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Samuli Eldfors
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | | | | | - Imre Västrik
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Pekka Ellonen
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Matti Kankainen
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Minna Suvela
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Siv Knappila
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Alun Parson
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Aino Palva
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Pirkko Mattila
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | | | - Laura Turunen
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | | | - Elina Lehtinen
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Maria Nurmi
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | - Katja Suomi
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | | | | | - Satu Mustjoki
- 2Hematology Research Unit Helsinki, Helsinki, Finland
| | - Simon Anders
- 4Center for Molecular Biology of University of Heidelberg (ZMBH), Heidelberg, Germany
| | - Maija Wolf
- 1Inst. for Molec. Medicine Finland (FIMM), Helsinki, Finland
| | | | | | | | - Kimmo Porkka
- 2Hematology Research Unit Helsinki, Helsinki, Finland
| | | |
Collapse
|
3
|
Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia 2016; 31:1187-1195. [PMID: 27833094 PMCID: PMC5420795 DOI: 10.1038/leu.2016.314] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Revised: 09/22/2016] [Accepted: 09/26/2016] [Indexed: 12/20/2022]
Abstract
We sought to identify drugs that could counteract cytarabine resistance in acute myeloid leukemia (AML) by generating eight resistant variants from MOLM-13 and SHI-1 AML cell lines by long-term drug treatment. These cells were compared with 66 ex vivo chemorefractory samples from cytarabine-treated AML patients. The models and patient cells were subjected to genomic and transcriptomic profiling and high-throughput testing with 250 emerging and clinical oncology compounds. Genomic profiling uncovered deletion of the deoxycytidine kinase (DCK) gene in both MOLM-13- and SHI-1-derived cytarabine-resistant variants and in an AML patient sample. Cytarabine-resistant SHI-1 variants and a subset of chemorefractory AML patient samples showed increased sensitivity to glucocorticoids that are often used in treatment of lymphoid leukemia but not AML. Paired samples taken from AML patients before treatment and at relapse also showed acquisition of glucocorticoid sensitivity. Enhanced glucocorticoid sensitivity was only seen in AML patient samples that were negative for the FLT3 mutation (P=0.0006). Our study shows that development of cytarabine resistance is associated with increased sensitivity to glucocorticoids in a subset of AML, suggesting a new therapeutic strategy that should be explored in a clinical trial of chemorefractory AML patients carrying wild-type FLT3.
Collapse
Affiliation(s)
- D Malani
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - A Murumägi
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - B Yadav
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - M Kontro
- Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
| | - S Eldfors
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - A Kumar
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - R Karjalainen
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - M M Majumder
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - P Ojamies
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - T Pemovska
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - K Wennerberg
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - C Heckman
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - K Porkka
- Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
| | - M Wolf
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
| | - T Aittokallio
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.,Department of Mathematics and Statistics, University of Turku, Turku, Finland
| | - O Kallioniemi
- Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland.,Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, Solna, Sweden
| |
Collapse
|
4
|
Koskela A, Reinisalo M, Olmiere C, Petrovski G, Sinha D, Karjalainen R, Kaarniranta K. Resvega induces autophagy and prevents ARPE-19 cell damage during proteasome inhibition. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Naillat F, Yan W, Karjalainen R, Liakhovitskaia A, Samoylenko A, Xu Q, Sun Z, Shen B, Medvinsky A, Quaggin S, Vainio SJ. Identification of the genes regulated by Wnt-4, a critical signal for commitment of the ovary. Exp Cell Res 2015; 332:163-78. [DOI: 10.1016/j.yexcr.2015.01.010] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Revised: 12/23/2014] [Accepted: 01/21/2015] [Indexed: 11/30/2022]
|
6
|
Elo LL, Karjalainen R, Ohman T, Hintsanen P, Nyman TA, Heckman CA, Aittokallio T. Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia. Proteomics 2014; 14:2443-53. [PMID: 25211154 DOI: 10.1002/pmic.201300460] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Revised: 07/31/2014] [Accepted: 09/08/2014] [Indexed: 12/12/2022]
Abstract
The increasing coverage and sensitivity of LC-MS/MS-based proteomics have expanded its applications in systems medicine. In particular, label-free quantitation approaches are enabling biomarker discovery in terms of statistical comparison of proteomic profiles across large numbers of clinical samples. However, it still remains poorly understood how much protein markers can add novel insights compared to markers derived from mRNA transcriptomic profiling. Using paired label-free LC-MS/MS and gene expression microarray measurements from primary samples of patients with acute myeloid leukemia (AML), we demonstrate here that while the quantitative proteomic and transcriptomic profiles were highly correlated, in general, the marker panels showing statistically significant expression changes across the disease and healthy groups were profoundly different between protein and mRNA levels. In particular, the proteomic assay enabled unique links to known leukemic processes, which were missed when using the transcriptomic profiling alone, as well as identified additional links to metabolic regulators and chromatin remodelers, such as GPX1, fumarate hydratase, and SET oncogene, which have subsequently been evaluated in independent AML samples. Overall, these results highlighted the complementary and informative view obtained from the quantitative LC-MS/MS approach into the AML deregulated signaling networks.
Collapse
Affiliation(s)
- Laura L Elo
- Department of Mathematics and Statistics, University of Turku, Turku, Finland; Turku Centre for Biotechnology, Turku, Finland
| | | | | | | | | | | | | |
Collapse
|
7
|
Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, Majumder MM, Malani D, Murumägi A, Knowles J, Porkka K, Heckman C, Kallioniemi O, Wennerberg K, Aittokallio T. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep 2014; 4:5193. [PMID: 24898935 PMCID: PMC4046135 DOI: 10.1038/srep05193] [Citation(s) in RCA: 205] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Accepted: 05/20/2014] [Indexed: 01/17/2023] Open
Abstract
We developed a systematic algorithmic solution for quantitative drug sensitivity scoring (DSS), based on continuous modeling and integration of multiple dose-response relationships in high-throughput compound testing studies. Mathematical model estimation and continuous interpolation makes the scoring approach robust against sources of technical variability and widely applicable to various experimental settings, both in cancer cell line models and primary patient-derived cells. Here, we demonstrate its improved performance over other response parameters especially in a leukemia patient case study, where differential DSS between patient and control cells enabled identification of both cancer-selective drugs and drug-sensitive patient sub-groups, as well as dynamic monitoring of the response patterns and oncogenic driver signals during cancer progression and relapse in individual patient cells ex vivo. An open-source and easily extendable implementation of the DSS calculation is made freely available to support its tailored application to translating drug sensitivity testing results into clinically actionable treatment options.
Collapse
Affiliation(s)
- Bhagwan Yadav
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Tea Pemovska
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Agnieszka Szwajda
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Evgeny Kulesskiy
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Mika Kontro
- Hematology Research Unit, Helsinki University Central Hospital (HUCH), Helsinki, Finland
| | - Riikka Karjalainen
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | | | - Disha Malani
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Astrid Murumägi
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Jonathan Knowles
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Kimmo Porkka
- Hematology Research Unit, Helsinki University Central Hospital (HUCH), Helsinki, Finland
| | - Caroline Heckman
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Olli Kallioniemi
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Krister Wennerberg
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| | - Tero Aittokallio
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
| |
Collapse
|
8
|
Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JML, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013; 3:1416-29. [PMID: 24056683 DOI: 10.1158/2159-8290.cd-13-0350] [Citation(s) in RCA: 280] [Impact Index Per Article: 25.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
UNLABELLED We present an individualized systems medicine (ISM) approach to optimize cancer drug therapies one patient at a time. ISM is based on (i) molecular profiling and ex vivo drug sensitivity and resistance testing (DSRT) of patients' cancer cells to 187 oncology drugs, (ii) clinical implementation of therapies predicted to be effective, and (iii) studying consecutive samples from the treated patients to understand the basis of resistance. Here, application of ISM to 28 samples from patients with acute myeloid leukemia (AML) uncovered five major taxonomic drug-response subtypes based on DSRT profiles, some with distinct genomic features (e.g., MLL gene fusions in subgroup IV and FLT3-ITD mutations in subgroup V). Therapy based on DSRT resulted in several clinical responses. After progression under DSRT-guided therapies, AML cells displayed significant clonal evolution and novel genomic changes potentially explaining resistance, whereas ex vivo DSRT data showed resistance to the clinically applied drugs and new vulnerabilities to previously ineffective drugs. SIGNIFICANCE Here, we demonstrate an ISM strategy to optimize safe and effective personalized cancer therapies for individual patients as well as to understand and predict disease evolution and the next line of therapy. This approach could facilitate systematic drug repositioning of approved targeted drugs as well as help to prioritize and de-risk emerging drugs for clinical testing.
Collapse
Affiliation(s)
- Tea Pemovska
- 1Institute for Molecular Medicine Finland, FIMM; 2Hematology Research Unit Helsinki, Helsinki University Central Hospital, University of Helsinki, Helsinki; 3Department of Clinical Chemistry and TYKSLAB, Turku University Central Hospital, University of Turku, Turku; 4Department of Internal Medicine, Tampere University Hospital, Tampere, Finland; 5Department of Clinical Science, Hematology Section, University of Bergen; and 6Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Malani D, Murumägi A, Pemovska T, Yadav B, Kulesskiy E, Tang J, Mpindi JP, Wolf M, Karjalainen R, Aittokallio T, Heckman C, Porkka K, Wennerberg K, Kallioniemi O. Abstract 5220: Identifying AML-specific key targeted drugs using high-throughput drug sensitivity and resistance testing profiles of AML cells. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-5220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Conventional cytotoxic chemotherapy regimens for adult acute myeloid leukemia (AML) are effective in curing less than 50% of the patients, and there is a major need for targeted drugs with better anti-cancer selectivity. Here, our aim was to i) identify potential clinically used or emerging cancer drugs by quantitative drug sensitivity and resistance testing (DSRT) of 16 AML cell lines ii) compare the cell line data with results obtained from tested 24 ex vivo AML patient specimens iii) identify genomic correlations potentially explaining drug responsiveness.
Methods: The cancer pharmacopeia-wide drug collection is composed of 119 FDA approved and 90 investigational chemical compounds including cytotoxic agents and cell signaling molecule inhibitors. Each drug was tested over a 10,000-fold concentration range and that has generated quantitative five point dose-response curves. AML cells were plated in 384 well plates (where the drugs were pre-printed using an acoustic nano-dispensing technology, Labcyte®) and incubated in standard cell culture conditions. Cell viability was measured by Cell Titer Glow® luminescence assays. Analysis of dose response curves using Dotmatics® software resulted in IC50 values. Moreover, the genomic profiles of the AML cell lines were determined by microarrays and/or next-gen sequencing data for further integration with drug responses.
Results: Comprehensive data analysis of 16 AML cell lines indicated that specific targeted drugs were selectively killing AML cells. The data analysis revealed relatively strong responses for MEK inhibitors in most AML cell lines (e.g. refametinib 87%, trametinib 82%, selumetinib 75%) while 21% of ex vivo AML patient samples were sensitive to these MEK inhibitors. In case of rapalog sensitivity, 80% of AML cell lines (e.g. temsirolimus 82%, everolimus 71%, sirolimus 81%) and 25% of ex vivo AML patient cases were responsive to the mTOR inhibitors. The AML cell lines carrying FLT3-ITD mutations were extremely sensitive to FLT3 inhibitors (e.g. quizartinib, lestaurtinib, tandutinib, and sorafenib) but very few responses to FLT3 inhibitors were observed in AML patients carrying an ITD mutation in the FLT3 kinase.
Summary: Systematic DSRT profiling of AML cell lines illustrates drug sensitivity patterns to classify the cell lines as sensitive or resistant to specific classes of drugs. mTOR and MEK inhibitors were among the most effective inhibitors for most cell lines and also in some ex vivo patient cases suggesting that these drugs may have potential as therapeutic agents in AML. Also, bioinformatics predictions can be used to identify key synergistic combinations of tested drugs for effective AML therapy. Further integration of molecular profiles and functional responses of AML cell lines will help provide better understanding of drug efficacy based on known genetic background of the disease.
Citation Format: Disha Malani, Astrid Murumägi, Tea Pemovska, Bhagwan Yadav, Evgeny Kulesskiy, Jing Tang, John Patrick Mpindi, Maija Wolf, Riikka Karjalainen, Tero Aittokallio, Caroline Heckman, Kimmo Porkka, Krister Wennerberg, Olli Kallioniemi. Identifying AML-specific key targeted drugs using high-throughput drug sensitivity and resistance testing profiles of AML cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5220. doi:10.1158/1538-7445.AM2013-5220
Collapse
Affiliation(s)
- Disha Malani
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | | | - Tea Pemovska
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Bhagwan Yadav
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | | | - Jing Tang
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | | | - Maija Wolf
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | | | | | | | - Kimmo Porkka
- 2Hematology Research Unit, Helsinki University Central Hospital, Helsinki, Finland
| | | | | |
Collapse
|
10
|
Pemovska T, Kylesskiy E, Kontro M, Szwajda A, Karjalainen R, Majumder MM, Malani D, Bespalov MM, Eldfors S, Elonen E, Knowles J, Murumägi A, Mpindi JP, Edgren H, Venkata NPK, Turunen L, Mustjoki S, Wolf M, Yadav B, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Identification of signaling pathways that are required for the growth and differentiation block of cells from adult acute myeloid leukemia (AML) is urgently required to facilitate development of novel therapies. Here, we describe an approach to functionally determine molecular drivers of AML by quantitative drug sensitivity and resistance testing (DSRT) of AML blast cells in primary culture ex vivo. The selection of drugs covered the entire cancer pharmacopeia and much of the pipeline of drugs under development in the industry: 120 FDA approved small molecular cancer drugs and 120 emerging drugs, investigational compounds and signal transduction inhibitors. All compounds were tested over a 10,000-fold concentration range to generate quantitative and reliable dose-response data. In addition, whole exome and transcriptome sequencing and phophoproteomic profiling were also performed to derive a comprehensive understanding of the molecular AML-related aberrations on an individual basis. Comparison of 17 AML patient samples and 3 healthy bone marrow control samples based on ex vivo drug responses identified several classes of approved and investigational drugs that showed selective anti-AML activities: mTOR inhibitors (e.g. temsirolomus, everolimus, sirolimus), MEK inhibitors (e.g. AS703026, GSK1120212, RDEA119, selumetinib), tyrosine kinase inhibitors (e.g. dasatinib, ponatinib, sunitinib), Bcl-2 inhibitors (navitoclax) and HSP90 inhibitors (e.g. BIIB021, NVP-AUY922, tanespimycin). In particular, the rapamycin class of mTOR inhibitors and allosteric MEK inhibitors stood out as effective and selective inhibitors in 8/17 (47%) and 9/17 (52%) of the patients, respectively. Simultaneous data from other targeted inhibitors made it possible to dissect the critical steps in signaling and therapeutic efficacy. For example, PI3K and Akt inhibitors were not effective in these patients, suggesting that the mTOR dependency is mediated through a PI3K-Akt-independent pathway. Similarly, the dependency of MEK signaling appears to be through a Ras-Raf-independent pathway since Raf inhibitors were not effective. In conclusion, the DSRT platform allows us to derive quantitative data on the ex vivo drug response profiles of AML cells from individual patients. This information could be used as a diagnostic tool to optimize personalized therapies in the future. Our data demonstrate that mTOR and MEK signaling and the associated inhibitors are the most promising leads for improved AML therapeutics. This analysis also demonstrates gaps in our current understanding of the redundancy of key cancer cell signaling pathways and proves the significant value of data from experimental drug response testing ex vivo.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 895. doi:1538-7445.AM2012-895
Collapse
Affiliation(s)
- Tea Pemovska
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Evgeny Kylesskiy
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Mika Kontro
- 2Hematology Research Unit, Helsinki University Central Hospital, Helsinki, Finland
| | | | | | | | - Disha Malani
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | | | - Samuli Eldfors
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Erkki Elonen
- 2Hematology Research Unit, Helsinki University Central Hospital, Helsinki, Finland
| | - Jonathan Knowles
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Astrid Murumägi
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - John P. Mpindi
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Henrik Edgren
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | | | - Laura Turunen
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Satu Mustjoki
- 2Hematology Research Unit, Helsinki University Central Hospital, Helsinki, Finland
| | - Maija Wolf
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Bhagwan Yadav
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | - Tero Aittokallio
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | | | - Kimmo Porkka
- 2Hematology Research Unit, Helsinki University Central Hospital, Helsinki, Finland
| | - Olli Kallioniemi
- 1Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
| | | |
Collapse
|
11
|
Karjalainen R, Eldfors S, Edgren H, Venkata NPK, Kontro M, Majumder MM, Murumägi A, Parsons A, Almusa H, Ellonen P, Lepistö M, Mattila P, Hannula S, Lagström S, Suvela M, Wolf M, Wennerberg K, Knowles JKC, Mustjoki S, Saarela J, Porkka K, Kallioniemi O, Heckman CA. Abstract 5067: Exome sequencing reveals both DNA sequence and copy number changes in AML: Potential driver changes and mechanisms of drug resistance revealed from serial samples from the same patients. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-5067] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite significant advances in characterizing the molecular genetics of AML, the clonal evolution of leukemic cells and the dynamic impact of genomic changes on the development of the disease and progression to drug resistance are not well understood. Here, we applied next-generation sequencing to quantify aberrant tumor subclones carrying specific mutant alleles of key cancer genes and developed a method to extract quantitative high-resolution copy number changes across the genome using exome sequencing data from matching cancer and normal DNA. Serial bone marrow (BM) samples collected from diagnosis to relapse to post-treatment drug resistance in a patient-centric manner made it possible to trace the clonal evolution of AML and to identify variants potentially involved in drug resistance. Exome sequencing from AML blast cells and normal skin biopsies was performed as part of the Finnish Hematology Registry and Biobanking (FHRB) effort. Consecutive paired samples from different patients revealed unique genetic patterns of clonal evolution and cancer progression in each patient. In a pre-resistant sample of one AML M5 patient, we identified four closely spaced insertions in the Wilm's Tumor (WT1) suppressor gene, none of which appear on the same sequence reads. This suggests the presence of multiple distinct leukemic subclones even before treatment resistance and underscores the strong selective advantage conferred by WT1 mutations. After relapse, one of the subclones was lost, and another one significantly increased suggesting that the relapse arose from the expansion of a pre-existing resistant subclone. In this patient, recurrent clones otherwise featured similar copy number changes and the same fusion genes as the primary diagnostic sample. In another AML patient developing recurrence an opposite pattern was observed: The relapsed, drug-resistant cells displayed an enormous increase of small microdeletions compared to the diagnostic, pre-treatment sample, while almost all sequence-level alterations in potential cancer genes were the same between the two samples. This suggests that a distinct type of DNA repair deficiency may have contributed to the drug resistant clone in this patient. Conclusions: Exome sequencing from paired samples of AML cells before and after relapse makes it possible to trace the clonal evolution of the disease and study the impact of therapy both at the level of sequence alterations of key cancer genes and simultaneously at the level of copy number changes inferred from exome sequence data. This analysis has highlighted multiple genomic patterns by which resistance may evolve in vivo during cancer treatment. Refined bioinformatic analysis and interpretation of exome-seq data provides a rich resource to identify genetic biomarkers of drug response and minimal residual disease.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5067. doi:1538-7445.AM2012-5067
Collapse
Affiliation(s)
| | - Samuli Eldfors
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Henrik Edgren
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | | | - Mika Kontro
- 2Hematology Research Unit, Department of Medicine, Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland
| | | | | | - Alun Parsons
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Henrikki Almusa
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Pekka Ellonen
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Maija Lepistö
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Pirkko Mattila
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Sari Hannula
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Sonja Lagström
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Minna Suvela
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Maija Wolf
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | | | | | - Satu Mustjoki
- 2Hematology Research Unit, Department of Medicine, Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland
| | - Janna Saarela
- 1Institute for Molecular Medicine Finland, Helsinki, Finland
| | - Kimmo Porkka
- 2Hematology Research Unit, Department of Medicine, Division of Hematology, Helsinki University Central Hospital, Helsinki, Finland
| | | | | |
Collapse
|
12
|
Malani D, Pemovska T, Kontro M, Murumägi A, Kulesskiy E, Yadav B, Bespalov M, Eldfors S, Elonen E, Karjalainen R, Knowles JKC, Majumder MM, Mpindi JP, Edgren H, Szwajda A, Venkata NPK, Turunen L, Mustjoki S, Wolf M, Aittokallio T, Heckman CA, Porkka K, Wennerberg K, Kallioniemi O. Abstract 3188: Development of a cancer pharmacopeia-wide ex-vivo drug sensitivity and resistance testing (DSRT) platform for AML: Towards individually optimized therapy and improved understanding of drug resistance patterns. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-3188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
In order to discover unexpected anti-cancer efficacies of approved and emerging drugs, we established a diagnostic ex vivo drug sensitivity and resistance testing (DSRT) platform covering the entire cancer pharmacopeia as well as emerging anti-cancer compounds. Here, the platform was applied to analyze bone marrow (BM) mononuclear cells from 17 adult acute myeloid leukemia (AML) patients, 3 healthy donors as well as 7 AML cell lines. The DSRT panel covered FDA-approved small molecule oncology drugs (n=120), as well as emerging, investigational and pre-clinical oncology compounds (n=120), such as kinase (e.g. RTKs, checkpoint and mitotic kinases, Raf, MEK, JAKs, mTOR, PI3K), and non-kinase inhibitors (e.g. HSP, Bcl, activin, HDAC, PARP, Hh). To generate dose-response curves, each of the drugs was applied over a 10,000-fold concentration range. In addition, the samples underwent deep molecular profiling including exome- and transcriptome sequencing, as well as phosphoproteomic analysis. DSRT provided consistent and reliable data from ex vivo samples with a high correlation between data from individual healthy BM samples (r=0.93). Bioinformatic processing of the data from AML resulted in several key observations. First, overall drug response profiles of AML blast cells were distinctly different from healthy BM controls suggesting several potential leukemia-selective effects, such as multi-kinase (dasatinib), MEK, and mTOR inhibitors. Second, the overall drug responses from AML cell lines and the patient ex vivo samples showed differences, suggesting that ex vivo testing may reveal cancer-selective effects not previously seen in established cancer cell line panels. Third, the response data from patient samples clustered many drugs consistently into the expected functional classes (such as topoisomerase II inhibitors, MEK inhibitors and rapalogs), whereas other drug classes were more dispersed (such as FLT3 inhibitors with quizartinib clustering away from all other tyrosine kinase inhibitors), suggesting secondary targets playing a key role in drug efficacy. Fourth, analysis of serial samples from patients developing clinical resistance to targeted agents showed striking agreement between the ex-vivo DSRT profiles and clinical responses. In conclusion, comprehensive DSRT platform generated powerful novel insights on AML drug response and may enable individual optimization of therapies, particularly for recurrent leukemias. DSRT will also serve as a powerful hypothesis-generator for clinical trials, particularly for emerging drugs. The ability to correlate ex vivo response profiles for hundreds of drugs in clinical samples with deep molecular profiling data will yield exciting new translational and pharmacogenomic opportunities for cancer therapy.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3188. doi:1538-7445.AM2012-3188
Collapse
Affiliation(s)
- Disha Malani
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | - Tea Pemovska
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | - Mika Kontro
- 2Hematology Research Unit, Helsinki University Central Hospital, Helsinki, Finland
| | - Astrid Murumägi
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | - Evgeny Kulesskiy
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | - Bhagwan Yadav
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | - Maxim Bespalov
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | - Samuli Eldfors
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | - Erkki Elonen
- 2Hematology Research Unit, Helsinki University Central Hospital, Helsinki, Finland
| | | | | | | | | | - Henrik Edgren
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | | | | | - Laura Turunen
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | - Satu Mustjoki
- 2Hematology Research Unit, Helsinki University Central Hospital, Helsinki, Finland
| | - Maija Wolf
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | - Tero Aittokallio
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| | | | - Kimmo Porkka
- 2Hematology Research Unit, Helsinki University Central Hospital, Helsinki, Finland
| | | | - Olli Kallioniemi
- 1Institute for Molecular Medicine Finland, FIMM, Helsinki, Finland
| |
Collapse
|
13
|
Peltoketo H, Strauss L, Karjalainen R, Zhang M, Stamp GW, Segaloff DL, Poutanen M, Huhtaniemi IT. Female mice expressing constitutively active mutants of FSH receptor present with a phenotype of premature follicle depletion and estrogen excess. Endocrinology 2010; 151:1872-83. [PMID: 20172968 PMCID: PMC2851188 DOI: 10.1210/en.2009-0966] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Strong gain-of-function mutations have not been identified in humans in the FSH receptor (FSHR), whereas such mutations are common among many other G protein-coupled receptors. In order to predict consequences of such mutations on humans, we first identified constitutively activated mutants of the mouse (m) Fshr and then expressed them under the human anti-Müllerian hormone promoter in transgenic mice or created knock-in mutation into the mouse genome. We show here that mutations of Asp580 in the mFSHR significantly increase the basal receptor activity. D580H and D580Y mutations of mFSHR bind FSH, but the activity of the former is neither ligand-dependent nor promiscuous towards LH/human choriogonadotropin stimulation. Transgenic expression of mFshr(D580H) in granulosa cells leads to abnormal ovarian structure and function in the form of hemorrhagic cysts, accelerated loss of small follicles, augmented granulosa cell proliferation, increased estradiol biosynthesis, and occasional luteinized unruptured follicles or teratomas. The most affected mFshr(D580H) females are infertile with disturbed estrous cycle and decreased gonadotropin and increased prolactin levels. Increased estradiol and prolactin apparently underlie the enhanced development of the mammary glands, adenomatous pituitary growth, and lipofuscin accumulation in the adrenal gland. The influence of the mFSHR(D580Y) mutation is milder, mainly causing hemorrhagic cysts in transgenic mFSHR(D580Y) and mFSHR(D580Y) -knock-in mice. The results demonstrate that gain-of-function mutations of the FSHR in mice bring about distinct and clear changes in ovarian function, informative in the search of similar mutations in humans.
Collapse
Affiliation(s)
- Hellevi Peltoketo
- Institute of Reproductive and Developmental Biology, 2nd floor, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Karjalainen R, Anttonen M, Saviranta N, Stewart D, McDougall G, Hilz H, Mattila P, Törrönen R. A REVIEW ON BIOACTIVE COMPOUNDS IN BLACK CURRANTS (RIBES NIGRUM L.) AND THEIR POTENTIAL HEALTH-PROMOTING PROPERTIES. ACTA ACUST UNITED AC 2009. [DOI: 10.17660/actahortic.2009.839.38] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
15
|
Carlen C, Faby R, Karjalainen R, Pommier J, Steffek R. CONTROL OF AIR BORNE DISEASE IN STRAWBERRIES WITH NATURAL AND SYNTHETIC ELICITORS. ACTA ACUST UNITED AC 2004. [DOI: 10.17660/actahortic.2004.649.44] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
16
|
|
17
|
Karjalainen R, Välimäki K, Pacot-Hiriart C, Kleemola M, Lehto K. OPTIMISING OF THE TRANSFORMATION METHODS OF BLACK CURRANT (Ribes nigrum L. ) AND DEVELOPMENT OF TRANSGENIC RESISTANCE AGAINST BLACK CURRANT REVERSION VIRUS. ACTA ACUST UNITED AC 2001. [DOI: 10.17660/actahortic.2001.560.29] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
18
|
Pääkkönen E, Vahala J, Holopainen T, Karjalainen R, Kärenlampi L. Growth responses and related biochemical and ultrastructural changes of the photosynthetic apparatus in birch (Betula pendula) saplings exposed to low concentrations of ozone. Tree Physiol 1996; 16:597-605. [PMID: 14871697 DOI: 10.1093/treephys/16.7.597] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Saplings of ozone-sensitive and ozone-tolerant birch (Betula pendula Roth.), clones B and C, respectively, were exposed to ozone concentrations that were 1.7-fold higher than ambient for one growing season under open-field conditions. Ambient air was used as the control treatment. In the ozone-sensitive clone B, there was an initial stimulation of leaf area growth in response to the ozone treatment, but further ozone exposure caused reductions in leaf and stem biomass growth, Rubisco and chlorophyll a contents, net photosynthesis, water use efficiency and chloroplast size. It also caused an alteration in chloroplast shape and injury to thylakoid membranes. In the ozone-tolerant clone C, ozone fumigation did not affect growth rate, and there were no consistent changes in chlorophyll content, photosynthesis or water use efficiency. There were also fewer ultrastructural abnormalities in the chloroplasts of clone C than of clone B. Based on the observed biochemical, physiological and structural changes in chloroplasts of clone B in response to low concentrations of ozone, we conclude that the increasing concentration of tropospheric ozone represents a risk to natural birch populations.
Collapse
Affiliation(s)
- E Pääkkönen
- Department of Ecology and Environmental Science, University of Kuopio, P.O. Box 1627, 70211 Kuopio, Finland
| | | | | | | | | |
Collapse
|
19
|
Abstract
A novel solution hybridization method for the diagnosis of a plant virus was evaluated. Synthetic oligonucleotide probes were used for the detection of potato virus X (PVX) in crude leaf sap extracts by hybridization in solution. Three 40-nucleotide-long oligonucleotide probes complementary to RNA sequences of potato virus X near the 3' end were synthesized. Two probes were 32P-labelled and one biotinylated. The three probes were allowed to form hybrids with the target viral nucleic acid in solution, and the formed hybrids were isolated with the aid of the biotinylated capture probe using avidin polystyrene beads after the reaction. Alternatively, hybrids were captured from the poly(A) tail of the viral RNA on oligo(dT) cellulose. The maximum signal was obtained after 4 h hybridization. About 70% of the maximum signal was obtained after 2 h hybridization. Sensitivity with the two 32P-labelled oligonucleotide probes was 1-5 x 10(7) molecules of PVX RNA. This corresponds to 0.6-3 ng of the virus. Crude leaf sap did not interfere with the detection of the virus. These results suggest that this solution hybridization method permits rapid detection of a plant virus in crude plant sap without sample pretreatment and may thus open new avenues for the development of a nucleic-acid-based ELISA-like diagnostic test for the detection of plant viruses.
Collapse
Affiliation(s)
- L Rouhiainen
- Department of Plant Pathology, University of Helsinki, Finland
| | | | | | | |
Collapse
|
20
|
Leung H, Lehtinen U, Karjalainen R, Skinner D, Tooley P, Leong S, Ellingboe A. Transformation of the rice blast fungus Magnaporthe grisea to hygromycin B resistance. Curr Genet 1990; 17:409-11. [PMID: 2357737 DOI: 10.1007/bf00334519] [Citation(s) in RCA: 58] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Low frequency, integrative transformation of three fertile hermaphroditic strains of Magnaporthe grisea has been achieved using plasmid pAN7-1 and cosmid pAN7-2, which contain an Escherichia coli hygromycin B phosphotransferase gene linked to Aspergillus nidulans regulatory sequences.
Collapse
Affiliation(s)
- H Leung
- Department of Plant Pathology, University of Wisconsin, Madison 53706
| | | | | | | | | | | | | |
Collapse
|
21
|
Katainen HS, Mäkinen E, Jokinen J, Karjalainen R, Kellomäki S. Effects of SO2 on the photosynthetic and respiration rates in scots pine seedlings. Environ Pollut 1987; 46:241-251. [PMID: 15092722 DOI: 10.1016/0269-7491(87)90171-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/1986] [Accepted: 02/03/1987] [Indexed: 05/24/2023]
Abstract
Exposure to moderate concentrations (90-500 microg SO(2) m(-3)) of SO(2) for 5-30 days caused a decrease in the photosynthetic rate. Only the lowest concentration (30 microg SO(2) m(-3)) increased photosynthesis. There was hardly any recovery in photosynthesis after the exposure. All exposure concentrations increased dark respiration. However, the lowest concentration had the smallest effect. Exposure to high concentration (2320 microg SO(2) m(-3)) of SO(2) for 5 h caused a strong decrease in the photosynthetic rate but there was a complete recovery within 2 weeks.
Collapse
Affiliation(s)
- H S Katainen
- Finish Forest Research Institute, Department of Soil Science, PO Box 18, SF-01301 Vantaa 30, Finland
| | | | | | | | | |
Collapse
|
22
|
|
23
|
Jokinen J, Karjalainen R, Kulmala A. Combined use of biological indicators and dispersion models in air pollution monitoring. Environ Monit Assess 1982; 2:411-415. [PMID: 24264352 DOI: 10.1007/bf00416699] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Affiliation(s)
- J Jokinen
- Finnish Meteorological Institute, Finland
| | | | | |
Collapse
|
24
|
Niemelä P, Lehtinen P, Rauramo L, Hermansson R, Karjalainen R, Mäki H, Storå CA. The first abortion - and the last? A study of the personality factors underlying repeated failure of contraception. Int J Gynaecol Obstet 1981; 19:193-200. [PMID: 6120865 DOI: 10.1016/0020-7292(81)90061-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The causes leading to a second abortion were outlined in a psychological study comparing 30 women expecting a second abortion with 29 women who had successfully prevented conception after a first abortion. It was found that both groups improved their contraceptive practices after the first abortion. However, while the latter group continued with their improved practices, the former group went back to the earlier inefficient or non-existent contraceptive behavior. The inability to improve contraception in the long run was not related to differences in educational level or knowledge about contraceptive techniques but to the developmental level of personality structures. The women expecting their second abortion rated lower in control of impulsivity, emotional balance, realism, self-esteem and stability of life as well as capacity for more integrated personal relationships. The differences in personality development and consequently in the capacity for long-term contraception were found to be due to growth conditions in childhood.
Collapse
|